期刊文献+

盐酸吉西他滨配伍卡铂治疗非小细胞肺癌50例临床观察

Clinical observation of combination chemotherapy with domesticgemcitabine (ZEFEI) plus carboplatin(CBP) in the treatmentof 50 cases of non-small-cell lung cancer
下载PDF
导出
摘要 目的:观察国产盐酸吉西他滨(泽菲)配伍卡铂治疗非小细胞肺癌(NSCLC)的近期疗效及毒副作用。方法:初治NSCLC病例50例,以28d为1周期。采用第1、8天泽菲1.0g/m2,维泵静脉推注,第1天卡铂按AUC=5~6静脉滴注,连用两个周期后评价疗效及毒副作用。结果:全组50例,有效率为44.0%(22/50),主要毒副作用为胃肠反应(Ⅲ~Ⅳ级是6.0%)和血液学毒性,Ⅲ~Ⅳ级白细胞下降和血小板下降分别为10.0%和2.0%。结论:泽菲配伍卡铂治疗NSCLC有较好疗效,毒副作用小,患者耐受性好。 Objective: To observe the short term efficacy and toxicity reactions of domestic gemcitabine (ZEFEI) plus carboplatin (CBP) in the treatment of advanced non-small-cell lung cancer (NSCLC). Methods,50 cases of previously untreated patients with advanced NSCLC were given domestic gemeitabine (ZEFEI) on day 1.8 at a dose of 1.0g/m^2 and earboplatin at a dose of AUC=5-6 on day 1. The chemotherapy was repeated every 28 days with two cycles. Results:The response rate was 44. 0 (22/50), and the main toxicity reactions were nausea/vomiting (Ⅱ - Ⅳgrade 6.0%) and hematological toxicity, Ⅱ - Ⅳ grade leukopenia and thrombocytopenia were 10.0% and 2.0% respectively. Conclusion: The domestic gemcitabine (ZEFEI) plus carboplatin combination is a highly effective regimen for patients with advanced NSCLC, with a manageable toxicity.
出处 《陕西医学杂志》 CAS 北大核心 2006年第5期593-595,共3页 Shaanxi Medical Journal
关键词 诊断 药物疗法 嘧啶核苷类 卡铂 非小细胞肺癌 盐酸吉西他滨 Carcinoma, non-small-cell lung/diagnosis Carcinoma, non-small-cell lung/drug therapy Pyrimidine nucleosides/therapeutic use Carboplatin/therapeutic use
  • 相关文献

参考文献6

  • 1管忠震,陈茹琴,徐光川,李宇红,许立功,李龙云,刘叙仪,廖美琳,李金瀚.Gemcitabine治疗晚期非小细胞肺癌的临床研究[J].癌症,1999,18(3):241-245. 被引量:177
  • 2Bonomi P, Kim K, Chang A, et al. Phase Ⅲ trial comparing etoposide(E) cisplatin(C) versus taxol(T)with cisplatin-G-CSF (G) versus taxol-cisplatin in advanced non-small-cell lung cancer. An eastern cooperative oncology group (ECOG) trial. An Ecog Trial Proc ASCO,2004,15(1):382
  • 3Schiller i, Lu ZH, Vanghan L, et al. Comparison of four chemotherapy regimen for advanced non-small-cell lung cancer. N Engl I Med,2002,348(2):92
  • 4Sendler A, Michael J, David A, et al. Phase Ⅲ trial gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Onc,2000,18(2):122
  • 5Candra DR,Edelman MJ,Lara P, et al. Gemcitabine and plantinum combination in advanced non-small-cell lung cancer:an update. Lung Cancer, 2000,9 (Supply):2
  • 6李卫东,金川,马磊,申维玺,邹青峰,吴迪.吉西他滨联合顺铂治疗Ⅲ~Ⅳ期非小细胞肺癌的临床观察[J].临床肿瘤学杂志,2005,10(1):43-44. 被引量:4

二级参考文献9

  • 1Gatzemeier U. Shepherd FA, Le Chevalier T, et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase Ⅱ study[J]. Eur J Cancer. 1996,32A: 243 -248.
  • 2Bonomi P,Kim K,Chang A,et al. Phase Ⅲ trial comparing etoposide (E) cisplatin (C) versus taxol (T) with cisplatin-G-CSF (G) versus taxobcisplatin in advanced non-small cell lung cancer. An eastern cooperative oncology group (ECOG) trial [ M ]. An Ecog trial Proc ASCO, 1996,15. 382.
  • 3Kelly K,Jassem J, Daniel P,et al. A randomized phase Ⅲ trial of pacilitaxol plus carboplatin versus vinorelbine plus cisplatin in untreated advanced non-small cell lung cancer:A Southwest Oncology Group(SWOG) trial[ J]. Proc Am Soc Onc, 1999,18:461a.
  • 4Sendler A,Michael J,David A,et al. Phase Ⅲ trial of gemcitabinep lus cisplatin versus clsplatin alone in patients with locally advanced or metastatic non-small cell lung cancer[ J]. J Clin Onc,2000,18:122 - 130.
  • 5Cometla,P. Interim analysis of a phase Ⅲ trial. Triple-vs. doubleagent chemotherapy for advauced non-small cell lung cancer. Southern ltaly Cooperative Oncology Guoup [J]. Oncology ( Huntingt) ,2000,14(7 Suppl 4) :35 -40.
  • 6Schiller, I. Lu ZH. Vanghan L, et al. Comparison of four chemotherapy regimen for advanced non-small cell lung cancer [ J ]. N Engl I Med,2002,346(2):92 -98.
  • 7Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine ( 2', 2'-deoxvcyticine) [ J ]. Cancer Res,1990,50(4) :4417 -4422.
  • 8Storniolo AM, Allerheriligen SBR, Pearce HL. Preclinical, pharmacologic and phase Ⅰ studies of gemcitabine [ J]. Semin Oncol,1997,24(2) :2 -7(Supp 7).
  • 9管忠震,陈茹琴,徐光川,李宇红,许立功,李龙云,刘叙仪,廖美琳,李金瀚.Gemcitabine治疗晚期非小细胞肺癌的临床研究[J].癌症,1999,18(3):241-245. 被引量:177

共引文献179

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部